Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The European Platform for the Responsible Use of Medicines in Animals (EPRUMA) has launched a new publication to tackle anthelmintic resistance.
Zoetis is to add to its Revolution (selamectin) canine parasiticide brand next year, by bringing a new product to market in the US.
European authorities have again recommended Boehringer Ingelheim's Longrange 50 mg/ml (eprinomectin) should not be approved.
A group of 90 researchers from 30 countries have gathered to share research and discuss coordinating an approach to developing solutions for anthelmintic resistance.
US agricultural products business American Vanguard (AMVAC) is to acquire the shares in TyraTech that it did not already own.
The US FDA is alerting pet owners and veterinarians of the possible adverse neurological events to cats and dogs associated with isoxazoline flea and tick products.
Covenant Animal Health Partners has been launched to focus on bringing animal health innovations to market.
Bayer Animal Health's Seresto flea and tick collar has recently been licensed in several European countries to reduce the risk of canine leishmaniasis.
Piedmont Animal Health and Norbrook Laboratories are among several firms to have gained recent product approvals from the US FDA.
Zoetis is aiming to get approval for a new three-way combination parasiticide, with launches penciled in for 2020.
Zoetis' Equitape praziquantel-only wormer for horses will be discontinued from the firm's equine product range in October 2018.
Boehringer Ingelheim Animal Health's NexGard antiparasitic chewable tablet for dogs has gained a supplemental approval from the US FDA for the prevention of a bacterial infection.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.